Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 71600

Title: Chinese Experts’ Consensus on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05495174

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: United Kingdom

Author’s Country/Territory: China

Manuscript submission date: 2021-09-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-20 00:36

Reviewer performed review: 2021-10-09 15:17

Review time: 19 Days and 14 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Re-review</th>
<th>[ ] Yes</th>
<th>[ ] No</th>
</tr>
</thead>
</table>
SPECIFIC COMMENTS TO AUTHORS
This consensus on neoadjuvant and conversion therapies for HCC is very well written and important to the clinicians. After a minor editing to the manuscript, it can be accepted for publication.
Name of journal: World Journal of Gastroenterology

Manuscript NO: 71600

Title: Chinese Experts’ Consensus on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05492016

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: Canada

Author’s Country/Territory: China

Manuscript submission date: 2021-09-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-09-20 00:35

Reviewer performed review: 2021-10-09 15:23

Review time: 19 Days and 14 Hours

Scientific quality

[ ] Grade A: Excellent  [ Y] Grade B: Very good  [ ] Grade C: Good
[ ] Grade D: Fair  [ ] Grade E: Do not publish

Language quality

[ ] Grade A: Priority publishing  [ Y] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing  [ ] Grade D: Rejection

Conclusion

[ ] Accept (High priority)  [ Y] Accept (General priority)
[ Y] Minor revision  [ ] Major revision  [ ] Rejection

Re-review

[ Y] Yes  [ ] No
SPECIFIC COMMENTS TO AUTHORS
This consensus from Chinese presents the resultant evidence- and experience-based consensus to guide the application of neoadjuvant and conversion therapies of HCC in clinical practice. This consensus summaries the neoadjuvant and conversion therapies of HCC in a respectful manner, it can give the clinicians a detail guideline for the treatment of HCC. Overall, the manuscript is very well written. One question, the authors should consider to include the supplementary Tables as formal content, or re-number the references in the supplementary Tables and remove those references from the main reference list.